PMID- 12633573
OWN - NLM
STAT- MEDLINE
DCOM- 20031104
LR  - 20191106
IS  - 1043-4666 (Print)
IS  - 1043-4666 (Linking)
VI  - 20
IP  - 6
DP  - 2002 Dec 21
TI  - Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like 
      symptoms emerged in IL-6 transgenic mice.
PG  - 304-11
AB  - Transgenic mice carrying human IL-6 cDNA fused with a murine major 
      histocompatibility class-I promoter (H-2L(d)) were serially administered with 
      anti-interleukin-6 receptor (IL-6R) monoclonal antibody (mAb), MR16-1, from the 
      age of 4 weeks to estimate its efficacy on a variety of disorders developed in 
      these mice, most of which are similar to the disorders associated with 
      Castleman's disease. In the control mice treated with isotype-matched mAb, a 
      massive and multiple IgG1 plasmacytosis, mesangial proliferative 
      glomerulonephritis, leukocytosis, thrombocytosis, anemia and abnormalities of 
      blood chemical parameters have developed in accordance with the elevation of 
      serum IL-6, and 50% of mice have died of renal failure by 18 weeks of age. In 
      contrast, the treatment with MR16-1 prevented all these symptoms and prolonged 
      the lifetime of the majority of the mice. Thus, the constitutive overexpression 
      of IL-6 caused various disorders, and the treatment with anti-IL-6R mAb 
      completely prevented from these symptoms. These results clearly confirm that IL-6 
      indeed plays an essential role in the pathogenesis of a variety of disorders. 
      Furthermore, anti-IL-6R mAb could provide novel therapy for Castleman's disease 
      and MR16-1 should be a useful tool to estimate therapeutic potential of IL-6 
      antagonists in a variety of murine models for human disease.
CI  - Copyright 2003 Elsevier Science Ltd.
FAU - Katsume, Asao
AU  - Katsume A
AD  - Department of Medical Science I, School of Health and Sport Sciences, Osaka 
      University, Osaka, Japan. katsumeaso@chugai-pharm.co.jp
FAU - Saito, Hiroyuki
AU  - Saito H
FAU - Yamada, Yoshiki
AU  - Yamada Y
FAU - Yorozu, Keigo
AU  - Yorozu K
FAU - Ueda, Otoya
AU  - Ueda O
FAU - Akamatsu, Ken-ichi
AU  - Akamatsu K
FAU - Nishimoto, Norihiro
AU  - Nishimoto N
FAU - Kishimoto, Tadamitsu
AU  - Kishimoto T
FAU - Yoshizaki, Kazuyuki
AU  - Yoshizaki K
FAU - Ohsugi, Yoshiyuki
AU  - Ohsugi Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antibodies)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-6)
SB  - IM
MH  - Animals
MH  - Antibodies/*immunology/pharmacology
MH  - Castleman Disease/drug therapy/*immunology
MH  - Glomerulonephritis/immunology/prevention & control
MH  - Humans
MH  - Interleukin-6/*genetics
MH  - Kidney/immunology/pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - Receptors, Interleukin-6/*immunology
EDAT- 2003/03/14 04:00
MHDA- 2003/11/05 05:00
CRDT- 2003/03/14 04:00
PHST- 2003/03/14 04:00 [pubmed]
PHST- 2003/11/05 05:00 [medline]
PHST- 2003/03/14 04:00 [entrez]
AID - S1043466602920120 [pii]
AID - 10.1006/cyto.2002.2012 [doi]
PST - ppublish
SO  - Cytokine. 2002 Dec 21;20(6):304-11. doi: 10.1006/cyto.2002.2012.